6,650
+1.37%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SD Biosensor
Its shares trade on KRX under the ticker 137310.KS. It has been listed since 16 July 2021. In the fiscal year to 31 December 2025, it reported revenue of ₩710.58bn and a net loss of ₩512.11bn. At that date it held total assets of ₩3.24trn and shareholders' equity of ₩2.33trn.
SD Biosensor, Inc. develops and manufactures cholesterol, blood glucose testing and monitoring equipment. The company is headquartered in Suwon, Gyeonggi-Do. The company went IPO on 2021-07-16. The firm is engaged in the immunochemical diagnosis, molecular diagnosis, point-of-care diagnosis (POCTs), and self blood glucose measurement business. The firm is engaged in the research, development and sale of products such as rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, enzyme immunological reaction diagnosis products and others. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 16 Jul 2021
- Website
- sdbiosensor.co.kr ↗
Leadership
Pay as last reported
- Mr. Yeong Sik ChoChairman₩540.0m
- Mr. Won Gi MinPresident
- Mr. Tae Yeong HuhCo-Chief Executive Officer, Director, since 2021₩7.98bn
- Mr. Hyo Geun LeeCo-Chief Executive Officer, Director, since 2021₩563.0m
- Mr. Ho Gyeong YooChief Financial Officer, Assistant Managing Director
- Ms. Hye Yim ChoVice President, Director, since 2021₩543.0m
- Mr. Yun Seok JinManaging Director
- Mr. Won Seok JooAssistant Managing Director
- Mr. Ju Han KimAssistant Managing Director
- Mr. Seong Ho KimAssistant Managing Director
- Mr. Seok Ju LeeAssistant Managing Director
- Mr. Seon Yeong LeeAssistant Managing Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 89
- Social
- 30
- Governance
- 38
- Direct emissions (scope 1)
- 1,180 t
- Energy emissions (scope 2)
- 14,995 t
- Women in the workforce
- 42%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SD Biosensor's cholesterol testing equipment is widely used in South Korea's healthcare system.
- The company's POCTs are popular in the point-of-care diagnosis segment globally.
- Rapid immunochemical diagnosis products are key in the domestic market for quick results.
Weaknesses
- Limited international market presence beyond South Korea's domestic market.
- Dependence on the domestic market for a significant portion of revenue.
- Lack of expansion into emerging markets like Southeast Asia.
Opportunities
- Growing demand for blood glucose monitoring in aging populations worldwide.
- Expanding molecular diagnosis products in the global health care sector.
- Increasing adoption of POCTs in developing countries for better healthcare access.
Threats
- Intense competition from established health care companies in the global market.
- Regulatory changes affecting medical device approvals in key markets.
- Economic downturns impacting healthcare spending in developed nations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.